NASDAQ:GDRX GoodRx (GDRX) Stock Price, News & Analysis $8.85 +0.11 (+1.26%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$8.66▼$8.9050-Day Range$7.13▼$8.9752-Week Range$4.14▼$9.37Volume506,065 shsAverage Volume1.43 million shsMarket Capitalization$3.32 billionP/E RatioN/ADividend YieldN/APrice Target$9.32 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get GoodRx alerts: Email Address GoodRx MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.55 Rating ScoreUpside/Downside5.3% Upside$9.32 Price TargetShort InterestBearish10.80% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.55Based on 5 Articles This WeekInsider TradingN/AProj. Earnings Growth47.06%From $0.17 to $0.25 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.18 out of 5 starsMedical Sector756th out of 936 stocksData Processing & Preparation Industry43rd out of 58 stocks 2.3 Analyst's Opinion Consensus RatingGoodRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.55, and is based on 12 buy ratings, 7 hold ratings, and 1 sell rating.Amount of Analyst CoverageGoodRx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about GoodRx's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.80% of the float of GoodRx has been sold short.Short Interest Ratio / Days to CoverGoodRx has a short interest ratio ("days to cover") of 6.5.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldGoodRx does not currently pay a dividend.Dividend GrowthGoodRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GDRX. Previous Next 2.0 News and Social Media Coverage News SentimentGoodRx has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for GoodRx this week, compared to 6 articles on an average week.Search InterestOnly 5 people have searched for GDRX on MarketBeat in the last 30 days. This is a decrease of -58% compared to the previous 30 days.MarketBeat Follows3 people have added GoodRx to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GoodRx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.17% of the stock of GoodRx is held by insiders.Percentage Held by Institutions63.77% of the stock of GoodRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GoodRx's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for GoodRx are expected to grow by 47.06% in the coming year, from $0.17 to $0.25 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GoodRx is -884.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GoodRx is -884.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioGoodRx has a PEG Ratio of 4.18. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGoodRx has a P/B Ratio of 4.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about GoodRx's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad MarketBeatWe just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.Start Your Risk-Free Trial Here About GoodRx Stock (NASDAQ:GDRX)GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.Read More GDRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GDRX Stock News HeadlinesJuly 26 at 3:20 PM | 247wallst.comGoodRx Holdings Inc - Class AJuly 25 at 2:28 AM | americanbankingnews.comGoodRx Holdings, Inc. (NASDAQ:GDRX) Given Average Rating of "Moderate Buy" by BrokeragesJuly 26, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.July 19, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV), GoodRx Holdings (GDRX) and Organon (OGN)July 19, 2024 | markets.businessinsider.comGoodRx Holdings Underperform Rating: Concerns Over Biosimilar Affordability and Generic Reimbursement Market DynamicsJuly 19, 2024 | msn.comGoodRx partners with Boehringer Ingelheim to discount Humira biosimilarJuly 19, 2024 | msn.comGoodRx offers exclusive discount to biosimilar targeting AbbVie’s HumiraJuly 18, 2024 | prnewswire.comBoehringer Ingelheim and GoodRx announce exclusive patient affordability initiative for Adalimumab-adbm injection, Boehringer's biosimilar to Humira®July 26, 2024 | DTI (Ad)How a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…June 28, 2024 | investorplace.comMarket Correction Alert: Sell These 3 Tech Stocks While You CanJune 27, 2024 | cnbc.comDrug prices have risen almost 40% over the last decade, according to a new trackerJune 26, 2024 | pymnts.comGoodRx Debuts Tracker to Monitor Out-of-Pocket Prescription CostsJune 26, 2024 | businesswire.comGoodRx Launches New “Prescription Cost Tracker” to Spotlight Key Factors Driving Out-of-Pocket Medication Costs in the U.S.June 21, 2024 | globenewswire.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of GoodRxJune 21, 2024 | businesswire.comGDRX Investors Have Opportunity to Lead GoodRx Holdings, Inc. Securities Fraud Lawsuit with the Schall Law FirmJune 21, 2024 | businesswire.comGoodRx Holdings, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - GDRXJune 21, 2024 | prnewswire.comLost Money on GoodRx Holdings, Inc.(GDRX)? Join Class Action Suit Seeking Recovery - Contact Levi & KorsinskyJune 20, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against GoodRx Holdings, Inc. (GDRX)See More Headlines Receive GDRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GoodRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Confirmed)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Data processing & preparation Sub-IndustryN/A Current SymbolNASDAQ:GDRX CUSIPN/A CIK1809519 Webwww.goodrx.com Phone855-268-2822FaxN/AEmployees694Year FoundedN/APrice Target and Rating Average Stock Price Target$9.32 High Stock Price Target$16.00 Low Stock Price Target$4.50 Potential Upside/Downside+5.3%Consensus RatingModerate Buy Rating Score (0-4)2.55 Research Coverage20 Analysts Profitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E RatioN/A Forward P/E Ratio52.06 P/E Growth4.18Net Income$-8,870,000.00 Net Margins-0.86% Pretax Margin-7.70% Return on Equity3.45% Return on Assets1.70% Debt Debt-to-Equity Ratio1.02 Current Ratio6.29 Quick Ratio6.29 Sales & Book Value Annual Sales$764.16 million Price / Sales4.35 Cash Flow$0.41 per share Price / Cash Flow21.73 Book Value$1.93 per share Price / Book4.59Miscellaneous Outstanding Shares375,205,000Free Float359,559,000Market Cap$3.32 billion OptionableOptionable Beta1.39 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Trevor Bezdek (Age 46)Co-founder & Chairman Comp: $537kMr. Douglas Joseph Hirsch (Age 53)Co-founder, Chief Mission Officer & Director Comp: $507.29kMr. Karsten Ian Voermann (Age 54)CFO & Principal Financial Officer Comp: $693.69kMr. Romin Nabiey (Age 36)Chief Accounting Officer & Principal Accounting Officer Comp: $516kMr. Scott W. Wagner (Age 53)Interim CEO & Principal Operating Officer Mr. Mike WalshPresident & Executive VP of Prescription MarketplaceMs. Whitney NotaroVice President of Investor RelationsMs. Gracye ChengGeneral Counsel & SecretaryMr. Andrew Slutsky (Age 37)Chief Marketing Officer Comp: $864.8kMs. Vina M. Leite (Age 54)Chief People Officer More ExecutivesKey CompetitorsDada NexusNASDAQ:DADAZendeskNYSE:ZENToastNYSE:TOSTRedditNYSE:RDDTGlobantNYSE:GLOBView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpSold 5,597 shares on 7/26/2024Ownership: 0.045%Legato Capital Management LLCBought 103,187 shares on 7/26/2024Ownership: 0.028%Liontrust Investment Partners LLPBought 66,615 shares on 7/26/2024Ownership: 0.018%Walleye Trading LLCSold 21,800 shares on 5/17/2024Ownership: 0.000%Beacon Capital Management LLCBought 4,000 shares on 5/17/2024Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions GDRX Stock Analysis - Frequently Asked Questions How have GDRX shares performed this year? GoodRx's stock was trading at $6.70 at the start of the year. Since then, GDRX stock has increased by 32.1% and is now trading at $8.85. View the best growth stocks for 2024 here. How were GoodRx's earnings last quarter? GoodRx Holdings, Inc. (NASDAQ:GDRX) released its quarterly earnings data on Thursday, May, 9th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.04 by $0.01. The company earned $197.88 million during the quarter, compared to the consensus estimate of $196.20 million. GoodRx had a positive trailing twelve-month return on equity of 3.45% and a negative net margin of 0.86%. When did GoodRx IPO? GoodRx (GDRX) raised $900 million in an initial public offering (IPO) on Wednesday, September 23rd 2020. The company issued 34,600,000 shares at $24.00-$28.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and Barclays served as the underwriters for the IPO and BofA Securities, Citigroup, Credit Suisse, RBC Capital Markets, UBS Investment Bank, Cowen, Deutsche Bank Securities, Evercore ISI, Citizens Capital Markets, KKR, LionTree, Raymond James, SVB Leerink, Academy Securities, Loop Capital Markets, R. Seelaus and Ramirez were co-managers. Who are GoodRx's major shareholders? GoodRx's top institutional investors include Bank of New York Mellon Corp (0.04%), Legato Capital Management LLC (0.03%), Liontrust Investment Partners LLP (0.02%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include Scott Wagner, Idea Men, Llc, Abdiel Capital Management, Llc, Trevor Bezdek, Agnes Rey-Giraud, Babak Azad, Karsten Voermann, Bansi Nagji, Andrew Slutsky and Douglas Joseph Hirsch. View institutional ownership trends. How do I buy shares of GoodRx? Shares of GDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of GoodRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that GoodRx investors own include Gilead Sciences (GILD), NVIDIA (NVDA), AbbVie (ABBV), Bristol-Myers Squibb (BMY), DraftKings (DKNG), GW Pharmaceuticals (GWPH) and Rocket Companies (RKT). This page (NASDAQ:GDRX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GoodRx Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GoodRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
